Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 1, 2008, Pages 77-82

  Moreno, Daniel ^a   Trocóniz, Iñaki F ^a   Enguita, Mónica ^a   Bandrés, Eva ^b   García Foncillas, Jesús ^b   Garrido, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASPASE 3; CISPLATIN; TOPOTECAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; HALF LIFE TIME; IN VITRO STUDY; NONHUMAN; RAT; SIGNAL TRANSDUCTION;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; RATS; SIGNAL TRANSDUCTION; TIME FACTORS; TOPOTECAN;

EID: 38349101995     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.1.0010     Document Type: Article

References (26)

1. Beal, S. L., Sheiner, L. B. (1992) NONMEM User's Guides. San Francisco, CA, NONMEM Project Group, University of California at San Francisco
2. Berndtsson, M., Hägg, M., Panaretakis, T., Havelka, A. M., Shoshan, M. C., Linder, S. (2007) Acute apoptosis by cisplatin requires induction of reactive species but is not associated with damage to nuclear DNA. Int. J. Cancer 120: 175-180
3. Clements, M. K., Jones, C. B., Cumming, M., Daoud, S. S. (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 44: 411-416
4. Cubedo, E., Cordeu, L., Bandrés, E., Rebollo, A., Malumbres, R., Sanmartin, C., Font, M., Palop, J. A., García-Foncillas, J. (2006) New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells. Cancer Biol. Ther. 5: 850-859
5. Cummings, B. S., Schnellmann, R. G. (2002) Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 302: 8-17
6. de Jonge, M. J. A., Loos, W. L., Gelderblom, H., Planting, A. S. Th., van der Burg, M. E. L., Sparreboom, A., Brouwer, E., van Beurden, V., Mantel, M. A., Doyle, E., Hearn, S., Ross, G., Verweij, J. (2000) Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J. Clin. Oncol. 18: 2104-2115
7. Feeney, G. P., Errington, R. J., Wiltshire, M., Marquez, N., Chappell, S. C., Smith, P. J. (2003) Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br. J. Cancer 88: 1310-1317
8. Gardner, S. N. (2000) A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and non-specific drugs. Cancer Res. 60: 1417-1425
9. Guchelaar, H.-J., Vermes, I., Koopmans, R. P., Reutelingsperger, Ch. P. M., Haanen, C. (1998) Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother. Pharmacol. 42: 77-83
10. Hassan, S. B., Jonsson, E., Larsson, R., Karlsson, M. O. (2001) Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J. Pharmacol. Exp. Ther. 299: 1140-1147
11. Kalns, J. E., Millenbaungh, N. J., Wientjes, M. G., Au, J. L. S. (1995) Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res. 15: 5315-5322
12. Kartalou, M., Essigmann, J. M. (2001) Mechanism of resistance to cisplatin. Mutat. Res. 478: 23-43
13. Kishimoto, S., Kawazoe, Y., Ikeno, M., Fukushima, S., Takeuchi, Y. (2005) Continuous exposure to low-dose cisplatin and apoptosis. Biol. Pharm. Bull. 28: 1954-1957
14. Lobo, E. D., Balthasar, J. P. (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS Pharm-Sci. 4: article 42 (http://www.aapspharmsci.org)
15. Löwik, C. W. G. M., Alblas, M. J., van de Ruits, M., Papapoulos, S. E., van der Pluijm, G. (1993) Quantification of adherent and non-adherent cells cultures in 96-well plates using the supravital stain neutral red. Anal. Biochem. 213: 426-433
16. Lupi, M., Matera, G., Branduardi, D., D'Incalci, M., Ubezio, P. (2004) Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer. Res. 64: 2825-2832
17. Montiel-Duarte, C., Varela-Rey, M., Oses-Prieto, J. A., López-Zabalza, M. J., Beitia, G., Cenarruzabeitia, E., Iraburu, M. J. (2002) 3,4-Methylenedioxy-methamphetamine ("Ecstasy") induces apoptosis of cultured rat liver cells. Biochim. Biophys. Acta. 1588: 26-32
18. Norton, L. (1988) Gompertzian model of human breast cancer growth. Cancer Res. 48: 7067-7071
19. Park, J. O., Lopez, C. A., Gupta, V. K., Brown, Ch. K., Mauceri, H. J., Darga, T. E., Manan, A., Hellman, S., Posner, M. C., Kufe, D. W., Weichselbaum, R. R. (2002) Transcriptional control of viral gene therapy by cisplatin. J. Clin. Invest. 110: 403-410
20. Segura, C., Bandrés, E., Trocóniz, I. F., García-Foncillas, J., Sayar, O., Dios-Viéitez, C., Renedo, M. J., Garrido, M. J. (2004) Hematological response of topotecan in tumor bearing rats: modeling of the time course of different cellular populations. Pharm. Res. 21: 567-573
21. Schoemaker, N. E., Herben, V. M., de Jong, L. A., van Waardenburg, R. C., Pluim, D., ten Bokkel Huinink, W. W., Beijnen, J. H., Schellens, J. H. (2002) Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study. Anticancer Drugs 13: 87-91
22. Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., Pesenti, E., Germani, M., Poggesi, I., Rocchetti, M. (2004) Predictive pharmacokinetic-pharmacodynamic modelling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64: 1094-1101
23. Ulukan, H., Swaan, P. W. (2002) Camptothecins. A review of their chemotherapeutic potential. Drugs 62: 20539-20574
24. Weyermann, J., Ochmann, D., Zimmer, A. (2005) A practical note on the use of cytotoxocity assays. Int. J. Pharm. 288: 369-376
25. Wu, Y. J., Muldoon, L. L., Neuwelt, E. A. (2004) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signalling pathway. J. Pharmacol. Exp. Ther. 312: 424-431
26. Zeghari-Squalli, H., Raymond, E., Cvitkovic, E., Goldwasser, F. (1999) Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer. Res. 5: 1189-1196